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Abstract
Supervised learning models, also known as quantitative structure-activity regression (QSAR)
models, are increasingly used in assisting the process of preclinical, small molecule drug dis-
covery. The models are trained on data consisting of a finite dimensional representation of
molecular structures and their corresponding target specific activities. These models can then
be used to predict the activity of previously unmeasured novel compounds. In this work we
address two problems related to this approach. The first is to estimate the extent to which the
quality of the model predictions degrades for compounds very different from the compounds
in the training data. The second is to adjust for the screening dependent selection bias in-
herent in many training data sets. In the most extreme cases, only compounds which pass an
activity-dependent screening are reported. By using a semi-supervised learning framework,
we show that it is possible to make predictions which take into account the similarity of the
testing compounds to those in the training data and adjust for the reporting selection bias.
We illustrate this approach using publicly available structure-activity data on a large set of
compounds reported by GlaxoSmithKline (the Tres Cantos AntiMalarial Set) to inhibit in
vitro P. falciparum growth.
1 Introduction
High-throughput experiments allow for the characterisation of the target specific activity of thou-
sands to hundreds of thousands of small molecules [1, 2]. The structure-activity data generated
from these experiments can be used to fit supervised learning models with the aim of then finding
molecular structures that are optimised to maximise multiple desired outcomes, such as target
activity, cytotoxicity, and lipophilicity [3]. However, many structure activity datasets have an in-
herent bias in that only molecules with a certain minimal target specific activity are characterised
and reported, e.g. [4], or few highly potent molecular structures are reported [5]. A bias towards
active molecules will result in overly optimistic predictions of the activity values of new molecules,
whereas models trained on data sets mostly comprising inactive molecules might hamper the dis-
covery of structurally novel active compounds [6, 7, 8]. In addition, it is well known that the quality
of the predictive model degrades as the similarity between the training and testing compounds de-
creases [9, 10, 11]. The set of testing compounds for which the predictive value of the model is
high is known as the applicability domain of the model [9]. This is often taken into account by
completely restricting models to the domain of compounds similar to those in the training set [9].
For a general predictive purposes however, we need ideally to produce a sensible answer for any
input compound [12].
In this work, we show that it is possible to explicitly adjust model predictions for both the activ-
ity dependent selection bias, and for the distance dependent predictive degradation by accounting
for the underlying geometry of molecular space. We use the Tanimoto distance as a metric on
molecular space, which has proved a suitable metric to quantify molecular similarity in multiple
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drug discovery applications [13]. The adjusted predictions are made using a semi-supervised learn-
ing framework. This takes as input a set of labelled compounds (structures with labelled activity
values) and a larger set of unlabelled compounds (only structures) which provide an empirical
representation of the overall distribution of ‘feasible’ small molecules, that is amenable to synthe-
sis and displaying drug-like properties [14]. Semi-supervised learning refers to the set of methods
developed in machine learning that use labelled (in this case structures with corresponding activ-
ity values) and unlabelled data (no corresponding activity values) to build predictive models, see
for example [15, 16]. The unlabelled data allow for a more accurate representation of the set of
‘feasible’ compounds that could have been part of the (unknown) screening process.
We illustrate this methodology on the Tres Cantos AntiMalarial Set (TCAMS), an open access
screening dataset based on the Plasmodium falciparum 3D7 asexual assay generated by Glaxo-
SmithKline (GSK) [4]. We fit random forest and ridge regression models to these data. We use
held-out data to compare the performance of the semi-supervised framework - which uses the
unlabelled data and explicitly adjusts for Tanimoto distance between testing and training data -
against the standard fully supervised framework.
2 Methods
2.1 Theoretical framework
2.1.1 Overview
It is generally considered that QSAR models provide reliable predictions for compounds similar
to those used as training data, but highly unreliable predictions otherwise [9, 12, 17]. Our work
attempts to formalise this intuition mathematically, assess the evidence for it, and build models
that can correct for this effect.
This ‘generalisability’ problem is illustrated in two ways by the TCAMS dataset, a large publicly
available set of compounds with measured IC50 values of the in vitro asexual activities against P.
falciparum 3D7. These data only contain screened compounds that inhibited 3D7 growth by more
than 80% at 2µM concentration. This introduces a selection bias for QSAR modelling, as only
compounds with considerable activity are reported. To correct for this bias we are assisted by two
sources of information. Firstly, the original TCAMS publication reported the number of compounds
which were screened, so we can estimate the fraction of compounds which passed this screening
threshold. Secondly, we can use available data on a very large number of known compounds that
approximately span known feasible compounds showing drug-like properties. These compounds
provide a rough approximation of the unknown compounds screened by GSK. In this work we use
2 million structures provided by Molport (a compound vendor). These structures are unlabelled,
i.e. they do not have an assigned activity value. However, we can use these structures to estimate
the probability that a compound is active against P. falciparum as a function of its distance to the
set of known (active) compounds. The following presents intuition behind the methodology.
For a compound that is entirely different to any of those in the training set of actives, its
activity value can be predicted using Bayes rule conditioning on the probability that it is active.
The probability that an entirely distinct compound is active is the background rate of actives
(0.7% in the TCAMS data). If it is active, then a reasonable prediction for the activity is the mean
observed activity of the active compounds. For a compound that is identical to one in the training
set, the prediction should approximately be the value corresponding to that training compound.
The question then is how to interpolate for compounds that fall in between these two scenarios.
We therefore wish to characterise how the mean activity changes as a function of the distance from
the training data.
The intuition behind our approach can be understood through the following analogy. Suppose
we have a map where the observed activity value for a given point on the map is the altitude above
sea level. Suppose we want to estimate how “jagged” the terrain is, where jagged measures how
quickly altitude changes between neighbouring points. Suppose further that many observations
have been made uniformly at random across the map, but only those with an altitude greater than
a given threshold were recorded. If the map is blank this implies there is no information content
as to the jaggedness of the terrain. If the recorded points are clustered together, this implies that
the terrain is divided into low and high regions; in other words, altitude varies smoothly. If on the
other hand the recorded points are not distinguishable from a set of points chosen uniformly at
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randomly on the map, this would indicate extremely jagged terrain. In our context the Tanimoto
distance puts all compounds onto a finite dimensional space corresponding to this map. The
unlabelled compounds are used to estimate the data generating process, i.e. an estimate of how
compounds are sampled across the ‘map’. This sampling procedure is very different from a uniform
distribution. By comparing the pairwise distances between the active compounds (recorded points)
to the pairwise distances between ‘random’ compounds (unlabelled data), we can estimate how
smoothly the activity varies as a function of distance to the active compounds.
2.1.2 Definitions and notation
We use the following notation throughout. Compounds (small molecules) are denoted x ∈ X , where
X is the unknown space of all feasible compounds. A compound x is represented by its ‘fingerprint’,
a binary vector of some fixed dimension p. This vector representation of x is constructed via a
‘fingerprint mapping’, which takes a fixed set of p chemical substructures and determines whether
or not these are substructures of x. In the resulting binary vector, a ‘1’ at index i indicates that
the ith substructure is a substructure of x, and a ‘0’ indicates that it is not. It is worth noting that
fingerprint mappings are not injective: two different compounds can have the same fingerprint,
and there are examples of this in the data we analyse [6, 18].
Identifying compounds by their fingerprint representation (for a given fingerprint mapping)
allows us to define a metric over molecular space. We use the Tanimoto distance (also known as
the Jaccard distance), defined as one minus the Tanimoto similarity [13]. The Tanimoto similarity
of two compounds xi and xj is the number of substructures common to both compounds, divided
by the total number of substructures that appear in at least one of the compounds [13]. Written as
boolean operators on binary vectors this is |xi∩xj |/|xi∪xj |. The rationale for choosing this metric
is that only sharing a particular substructure provides information regarding similarity, and two
compounds that share no substructures are thought of as being maximally different (for want of a
better model for representing molecules in a finite dimensional space). We denote the Tanimoto
distance between compounds xi, xj as d(xi, xj). For notational simplicity, we do not include the
dependency on the underlying fingerprint mapping. This mapping will affect the distance d, for
example increasing the number of structures p would increase the granularity of d. In addition
we define the setwise Tanimoto distance between a compound x and a set of compounds S as
d(x,S) = mins∈Sd(x, s). This is the Tanimoto distance between x and its nearest neighbour in S.
Our semi-supervised structure-activity regression modelling framework applies to the following
set-up, whereby there are two distinct sources of data. First, we have labelled structure-activity
data denoted Ln = {xi, yi}ni=1 (L for labelled), comprising n compounds. yi is the response value
for the compound xi. In our setting, yi is the target-specific activity of the compound xi for some
pre-defined target of interest, but in general it could represent other outcomes of interest (e.g. in
vitro cytotoxicity, or lipophilicity). The response yi is a (unknown) function of xi and as such can
be written yi = y(xi). In addition, the responses yi are all greater than a known cutoff value Lmin.
We denote as ‘actives’ the molecules with a response value above the Lmin, and as ‘inactives’ those
below the Lmin. The unknown set of all active molecules is denoted A. The compounds xi in
our structure-activity dataset Ln are a strict subset of A as they have been selected on the basis
of observed activities yi > Lmin. The set Ln was derived by screening a larger set of compounds
Ln′ (of known or unknown size n′ > n), and then choosing the active compounds amongst them:
Ln = Ln′ ∩ A. The critical point here is that the inactive compounds in the larger set Ln′ are
unknown or unavailable for analysis.
Second, we have unlabelled structure data of size N denoted UN (U for unlabelled). By con-
struction, there are no labelled compounds in UN (UN ∩ Ln = ∅). In general, in this set-up it is
assumed that n << N , which is that of many semi-supervised learning problems whereby there is
a smaller, well curated labelled data set, and a much larger unlabelled data set.
The key assumption that guides the following methodology is that the unlabelled data UN are
sampled from the same data generating process as the unknown set of screened compounds Ln′ . It
is worth noting that if we knew the structures in Ln′ then much of the framework developed here
would be unnecessary, but in practice the availability of large sets of active and inactive compounds
for a target of interest is rather limited [6], thus strongly limiting predictive modelling applications
in preclinical drug discovery. We also note that this assumption is, in general untestable, however
we show how specific deviations can be detected and corrected for.
3
2.1.3 Prediction goal of semi-supervised framework
Using the two data sources Ln and UN , we wish to determine the ranking of the individual molecules
in UN based on their probabilities of having an activity greater than some pre-specified threshold of
interest I. For example, this threshold could represent an activity high enough to warrant further
experiments. We note that in general a ranking based on tail probabilities (function of the mean
and higher moments of the distribution) will differ from a ranking based on mean predicted values.
Therefore, for each molecule x∗ ∈ UN , the goal is to estimate the probability that its activity y∗
is greater than the pre-specified threshold value I (where I is significantly greater than Lmin). To
estimate this probability, our modelling framework uses the labelled data Ln to fit a predictive
model of y given x, using the fingerprint representation of x ∈ Ln as a p-dimensional predictive
variable. We use Bayes rule, with the additional knowledge of the background frequency of active
compounds, to adjust for the inherent bias consequent to regressing onto an unrepresentative
sample of compounds. In addition, we use the unlabelled data to assess how the conditional
probability of being an active compound varies over molecular space. These adjustments are
necessary for the following reasons:
1. By construction, all the responses yi ∈ Ln have values greater than Lmin. Therefore, by
regression to the mean, a general regression model will predict for any new compound a
value greater than Lmin, regardless of the overall frequency of active compounds under the
data generating process (approximated by n′/n).
2. Using our metric d, we can observe whether the active compounds Ln are closer together than
compounds drawn from the same data generating process without selection bias. Assuming
that Ln were generated by taking the active compounds from a much larger set of compounds
generated from the same process that generates the unlabelled data, we can use the inter-
compound distances of Ln, compared to inter-compound distances of compounds from UN
to estimate the rate at which the probability of being active varies as function of distance to
the training data under the metric d.
Point 1 implies that it is necessary to adjust predictions with the background frequency of active
molecules; point 2 implies that a metric on molecular space along with the unlabelled data UN
provide key additional information as to whether a given molecule x∗ is active or not. Specifically,
we can use the information on the distance between x∗ and the training data Ln to inform the
prediction of y∗.
The prediction goal is expressed as the estimation of:
P [y∗ ≥ I|d(x∗,Ln)] (1)
By the law of total probability, conditioning on whether x∗ is active (i.e. y∗ > Lmin):
P [y∗ ≥ I|d(x∗,Ln)] = P [y
∗ ≥ I|d(x∗,Ln), x
∗ ∈ A]P [x∗ ∈ A|d(x∗,Ln)] (2)
The omitted second half of the sum with P [y∗ ≥ I|d(x∗,Ln), x∗ /∈ A], is equal to 0 as, by
definition, y∗ cannot be greater than I if x∗ is not in A.
In the next sections, we outline (i) the estimation of the distance dependent probability
that x∗ is active: P [x∗ ∈ A|d(x,Ln)]; and (ii) the estimation of the conditional probability that
y∗ > I: P [y∗ ≥ I|d(x∗,Ln), x∗ ∈ A]. We simplify the estimation of (ii) by breaking it down
into the predicted expected value of y∗, and the predicted uncertainty around this expected
value. Assuming a given parametric form for the predictive distribution of y∗, we can estimate
P [y∗ ≥ I|d(x∗,Ln), x∗ ∈ A]. This can be done by fitting a predictive distribution (conditional on
being active) using the active data we have - as explained in a section below - and then re-centering
and re-scaling using the mean and variance estimates from the predictive distribution.
2.1.4 Distance dependent probability that x∗ is active
Applying Bayes rule:
P [x∗ ∈ A|d(x∗,Ln)] =
P [x∗ ∈ A, d(x∗,Ln)]
P [d(x∗,Ln)]
(3)
=
P (x∗ ∈ A)P [d(x∗,Ln)|x∗ ∈ A]
P [d(x∗,Ln)]
(4)
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We estimate equation 4 by estimating each of its three components.
First, P [d(x∗,Ln)|x∗ ∈ A] can be estimated via a v-fold ‘cross-prediction’ type procedure. For
example, taking v = 2, we can randomly partition Ln into 2 equally sized subsets L1n/2,L
2
n/2. This
partition gives a total of n setwise distances for each element of L1n/2 to the set L
2
n/2, and vice
versa. By repeating this procedure k times, we obtain kn setwise distances which form an empirical
distribution of P
[
d(x∗,Ln/2)|x
∗ ∈ A
]
. The choice of v corresponds to a bias-variance trade-off.
Taking v = n (a leave-one-out procedure) results in n datasets that are likely to be highly similar
to one another, resulting in an empirical distribution of P [d(x∗,Ln−1)|x
∗ ∈ A] with high variance.
Lower values of v (e.g. v = 2) de-correlate the sets used to estimate these setwise distances and
result in a lower variance but with increased bias due to the smaller sample sizes.
Second, the denominator P [d(x∗,Ln)] can be estimated using the empirical distribution of
setwise distances d(x,Ln), where x ∈ UN . A sensitivity analysis with respect to the size of the set
Ln can be done by random samples of size n/2 elements from Ln.
Third, the marginal (prior) P (x∗ ∈ A), which is the overall fraction of active compounds in
X , can be estimated in two possible ways. If the number of compounds screened in order to
generate the data set Ln is known, then n over the number of compounds screened approximates
the overall fraction of actives in X . Otherwise, it is possible to use a limit argument. We assume
that compounds very close to an active compound are themselves active: formally this means that
limd(x∗,Ln)→0 P [x
∗ ∈ A|d(x∗,Ln)] = 1. Therefore:
P (x∗ ∈ A) = lim
d(x∗,Ln)→0
P [d(x∗,Ln)]
P [d(x∗,Ln)|x∗ ∈ A]
(5)
This relies on the ability to accurately estimate both terms in the ratio in equation 5. We
discuss this in section 2.2.2.
2.1.5 Distance-dependent degradation of predictive accuracy
In this section we show how to estimate the mean and variance of the predicted value of y∗ as
a function of the distance between x∗ and Ln, conditional on x∗ ∈ A. After fitting a model
M to the labelled data Ln, instead of using the ‘naive’ predicted expected value M(y∗|Ln) (and
modelled uncertainty around this estimate), we formally account for degradation in predictive
accuracy as a function of the distance d(x∗,Ln). By estimating this distance dependent decrease
in model accuracy we can correctly penalise model predictions to obtain a calibrated estimate of
P [y∗ ≥ I|d(x∗,Ln), x∗ ∈ A].
For a given distance δ ∈ [0, 1], we assess the ability of our predictive model M to extrapolate
at a distance δ from the training data by doing the following:
• We standardise the response values yi so that the model M is fit to approximately standard
normal data.
• For each compound xi ∈ Ln, we construct a subset of the labelled data, defined as all
compounds at least δ units of distance from xi. This is denoted L¯i,δ = {x ∈ Ln : d(x, xi) ≥ δ}.
This is the complement of the δ-ball centred around xi.
• We fit the model M to the data L¯i,δ and compute the out-of-sample prediction yˆMi,δ =
M(xi|L¯i,δ).
Here, M(a|B) denotes the prediction on compound a of the model M fit to data B. The δ-
distance prediction ‘quality’ of the model M can be assessed by the set of residuals {yi− yˆMi,δ}
n
i=1.
The decrease in predictive ability as a function of the setwise distance to the training data can be
quantified by estimating smooth functionals βˆ(δ), ǫˆ(δ), whereby:
yi ∼ N
(
βˆ(δ)yˆMi,δ , ǫˆ(δ)
2
)
(6)
The estimated standard deviation ǫˆ(δ) can be interpreted as 1 minus the distance-d R-squared of
the model M . The conditional predictive distribution of the response y∗ can then be estimated as:
y∗ ∼ N
(
βˆ[d(x∗,Ln)]M(x
∗|Ln), ǫˆ[d(x
∗,Ln)]
)
(7)
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2.1.6 Non-parametric estimation of distance dependent activity covariance
This section provides a non-parametric method for estimating the distance-dependent covariance
of the activity of two compounds. This can be used in two ways. First as a general approach for the
assessment of the ‘quality’ of a given p-dimensional fingerprint mapping. Second, as a conservative
estimator for the variance component in equation (7).
In general, for any two compounds xi, xj , the joint distribution of their respective activities
yi, yj can be estimated as
(
y¯ σ
σ y¯
)
, where y¯ is the mean activity value, and σ is the covariance.
If the distance metric over the fingerprint mapping of molecular space is a good representation of
the true distance between molecules (and therefore the true average difference in activities), then
this covariance σ will be a function of the distance d(xi, xj) and should be modelled accordingly.
With this aim, we define Bδ ⊂ Ln ×Ln as the set of all distinct pairs of active compounds for
which the pairwise distance is exactly δ:
Bδ = {x = (xi, xj) : d(xi, xj) = δ, xi 6= xj} (8)
The set Bδ can then be used to empirically estimate the distance-dependent covariance function
σ2(δ):
y(xi)− y(xj) ∼ N
[
0, σ(δ)2
]
, x = (xi, xj) ∈ Bd (9)
where N is the normal distribution.
2.2 Statistical methods
2.2.1 Data
To illustrate our predictive framework, we used the Tres Cantos Antimalarial Set (TCAMS) [4]
as the labelled data Ln. These data comprise 13,533 compounds, selected on the basis that they
inhibited the growth of Plasmodium falciparum 3D7 by at least 80% at 2 µM concentration (in
this context, this is the assay defining ‘active’ compounds and the threshold Lmin). This set of
compounds was discovered by screening a library of 1,985,056 compounds (an active discovery rate
equal to 0.68%) [4]. The structures for the inactive compounds were not reported, and hence, the
available structures correspond to only active compounds.
We constructed (see section 2.2.2) unlabelled datasets UN with publicly available data from the
Molport database after having removed all compounds with recorded activities in TCAMS (there
were 2044 compounds in Molport with canonical fingerprints equal to compounds in TCAMS,
which we count as identical in this case). This gave a total of N = 7, 228, 997 compounds with no
activity values (unlabelled).
Specific data issues in Molport dataset The key assumption used in the estimation of equa-
tion 4 is that the set UN is sampled from the same data generating process as the unknown set
Ln′ . This allows us to use UN to adjust for the inherent selection bias when training a supervised
regression model on Ln.
The set of unlabelled data UN was provided with a certain ordering (a set of numbered files,
each with approximately 500,000 compounds). This ordering was strongly correlated with the
setwise distance to the 13,533 compounds in the TCAMS dataset (labelled data). The MolPort
company could not provide a reason for this particular ordering of their data. It would seem likely
that the database was compiled over time, and thus the earlier compounds in the list are those
that are simpler to synthesise and thus more likely to appear in other high compound collections.
2.2.2 Distance-dependent probability of being active
The estimation of P [x∗ ∈ A|d(x∗,Ln)] is critical for the performance of the predictive model, see
Equation (2). This probability is proportional to the functional:
fn,N (δ) =
P [d(x,Ln) = δ|x ∈ A]
P [d(x,Ln) = δ]
(10)
where δ ∈ [0, 1]. An estimate fˆn,N(δ) of this functional should satisfy two properties:
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Figure 1: Visual representation of the activity data in TCAMS. Panel A: histogram of the
distribution of the negative log (base 10) IC50 of the compounds in the TCAMs data (n=13,533);
Panel B: histogram of the distribution of pairwise Tanimoto distances between molecules in the
TCAMs dataset under a 128-bit fingerprint representation (blue) and a 1024-bit fingerprint repre-
sentation (orange); Panel C: the same density histogram as in panel A, but with the y-axis on a
logarithmic scale, with the estimated mixture distribution used in the prediction procedure overlaid
(average of a normal and a student-t distribution).
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1. For δ = 0:
fˆn,N (0) =
1− ǫ
P (x∗ ∈ A)
where ǫ << 1 and depends on the granularity of the metric over molecular space.
2. fˆn,N (δ) is monotonically decreasing in δ ∈ [0, 1].
To estimate fˆn,N (δ): (i) we generate random samples from the distribution P [d(x,Ln) = δ|x ∈ A]
(the numerator); (ii) we generate random samples from the distribution P [d(x,Ln) = δ] (the de-
nominator); (iii) we use these two sets of random samples to determine a smooth estimate of the
ratio as a function of δ, such that the two properties specified above are satisfied. In this procedure,
γ is the bandwidth parameter of the Gaussian kernel density used to estimate both probability
densities for every value of δ (sklearn KernelDensity with default parameters).
The optimal value of γ is chosen as follows. First, we use the v-fold cross-prediction method to
sample from P [d(x,Ln) = δ|x ∈ A] with v = 2 and k = 5, giving a total of 66635 samples (input to
the numerator estimation). Second, we choose ten equally spaced distances δ in the range [0..0.45].
For each of these distances δ we choose 10 samples of 100,000 points from the MolPort database
using a specific sampling strategy explained below. We then use binary search to find the optimal
bandwidth γ such that the estimated fˆn satisfies the property fˆn(0) = 1..
This results in one hundred values for γ, and we take the median estimate γˆ. We then use this
γˆ to choose a value of δ such that samples chosen using this probability weighting, when smoothed
with bandwidth γ, have fn(0) = 1. This gives us values (rounded) of γ (bandwidth) = 0.09 and δ
(for use in our sampling strategy) = 0.15.
The structure of the Molport data UN , whereby compounds early on in the numbering are much
more likely to be close to the TCAMS dataset than those further on in the numbering motivates
the following importance sampling type approach to choosing an appropriate subset of the data
to use in fitting our estimate of P [d(x,Ln) = δ]. We generate sets of unlabelled data from UN ,
whereby the sampling probability decays as a function of the index of the unlabelled data using the
following crude approach. The Molport data is divided into fifteen files, in increasing order (with
500,000 compounds per file, apart from the last which only has half this amount). For a given
distance value δ, our sampling strategy goes as follows. We calculate the number of compounds
with minimum distance δ to the TCAMS data set, giving us nδ,i for i ∈ [0..14]. We sample from
file i (without replacement) with probability n(δ, i)/
∑
j(nδ,j).
Throughout this paper we used the python library scikit-learn [19] version 0.19.1 and functions
with default parameter settings except where stated otherwise.
2.2.3 Degradation of predictive accuracy
To calculate the distance dependent degradation functions βˆ(δ), ǫˆ(δ) (Equation 6), we choose a
uniform grid of 10 values of δ spanning the interval [0,1]. For each δ value on this grid, we
calculated βˆ(δ), ǫˆ(δ) as per Equation (6) where the underlying regression models were random
forests (RF) and ridge regression, respectively. We then used these ten estimates to interpolate
smooth functions βˆ(δ) and ǫˆ(δ) by minimizing least squares deviation. The function is of the form
g(δ) = a/(1 + e−bδ
c
). This function g is continuous, strictly decreasing and non-negative over the
interval [0, 1], with three free parameters (a, b, c).
2.2.4 Testing of predictive models
In order to benchmark the performance of the proposed predictive framework with respect to
simpler alternatives, we designed testing experiments. Training and testing data were selected on
the basis of quantiles of the distribution of the activity values [20]. In this set-up, all labelled data
with activity values below a chosen activity quantile qtrain are used as training data, and all labelled
data with activity values above a chosen activity quantile qtest are used as part of the testing data.
In particular, qtrain ≤ qtest. The complete testing set is then compose of these labelled data in
addition to a set of unlabelled data.
The thresholds used were qtrain = {7.0, 7.5}, and qtest = {7.5, 8.0}. In the TCAMS dataset,
there are 237 compounds with activity ≥ 7.5, and 170 compounds with activity ≥ 8.0. We denote
Xqtrain as the training data defined by the cut-off qtrain. We denote Mˆ(·|Xqtrain ) as the predictive
model (random forest or ridge regression) fit to the training data Xqtrain .
Each compound x∗ in the testing data is ranked according to the following four scores:
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1. S0(x
∗) = Mˆ(x∗|Xqtrain). This is the predicted mean value of y
∗. This is the unadjusted base
model.
2. S1(x
∗) = βˆ [d(x∗, Xqtrain ]S0(x
∗). This is the predicted mean value of y∗ scaled by the
distance-dependent penalty factor βˆ(δ), where δ is the setwise distance of x∗ from the training
data.
3. S2(x
∗) = P [x∗ ∈ A|d(x∗, Xqtrain)]S1(x
∗). This scores uses the additional reduction factor
which is the probability that x∗ is active given its distance from the training data.
4. S3(x
∗) = F
[
S2(x
∗), σ2 (d(x∗, Xqtrain))
]
P [x∗ ∈ A|d (x∗, Xqtrain )], where F (µ, σ, λ) is the pre-
dicted cumulative distribution function of y∗ with mean µ and variance σ. This is the full
model as specified in Equation (2).
Figure 1 shows the observed distribution of activities, which has a heavier tail than a Gaussian
distribution. A Gaussian approximation of the observed activities gives a mean value of 6.25 and
a standard deviation of 0.4, which implies that the expected number of compounds in the TCAMS
dataset with activity ≥ 8 is 0.08, whereas in fact there 170.
For the cumulative distribution function F in S3, we choose a mixture model which is a combi-
nation of a normal and a student t-distribution (shown in panel C of Figure 1). We use the standard
scikit-learn functions to fit a normal distribution to the activity data, and a Student-T distribution
to that same data. Our mixture model is then simply the average of these two distributions. 1
We use this same distribution, but with the new values of µ and σ to do our calculations for S3.
We implemented this fit using the inbuilt scipy fit functions, which fit distribution parameters to
data. We took as our model the average of the Normal fit to the activity data and the Student
T-distribution fit to the data. The approximation is shown against the density histogram in the
bottom panel of Figure 1.
Finally, we choose our unlabelled data in one of two ways: ‘well-specified’ and ‘mis-specified’.
This corresponding to choosing a set of unlabelled compounds using the sampling method described
above, which are closer or further to the TCAMS data, respectively. In each case we choose 500, 000
unlabelled compounds. We use the same methodology as that used in calculating the fraction of
actives to select the ’near’ dataset (recall, this consists in choosing from each file according to the
number of compounds with minimum distance 0.19 from the TCAMS dataset). The ‘far’ dataset
is chosen in the same way, but the fraction chosen from each file is the inverse of the number of
compounds at that distance. This selection methodology aims to thus test the sensitivity of our
results to the type of unlabelled data that the algorithm is searching over.
2.2.5 Limitations of methodology
A major limitation in the currently described methodology is that there is no propagation of
uncertainty between the independent estimates. Further work would put this process into a fully
Bayesian framework with uncertainty propagation. In addition, the solution to the estimation of
the ratio fn,N(δ) is only approximate and could possibly be improved.
2.3 Molecular Representation
We standardized all chemical structures in all data sets described above to a common representation
scheme using the python module standardizer (https://github.com/flatkinson/standardiser). Inor-
ganic molecules were removed, and the largest fragment was kept in order to filter out counterions[21].
To represent molecules for subsequent model generation, we computed circular Morgan fingerprints[18]
for all compounds using RDkit (release version 2013.03.02)[22]. Specifically, we computed hashed
Morgan fingerprints in binary format using the RDkit function GetMorganFingerprintAsBitVect,
which returns values in F1282 , and in count format, using in this case the RDkit function, GetH-
ashedMorganFingerprint, which returns values in N128.
We decided to use Morgan fingerprints as compound descriptors given the higher retrieval rates
obtained with this descriptor type in comparative virtual screening studies[23]. The radius was
set to 2 and the fingerprint length to 128. We note that longer fingerprints are associated with
1This is an extremely crude way of fitting a Normal and Student-T mixture distribution, but as shown in Figure
1 Panel C, it suffices to capture the fact that activity distribution has a long right tail, while also capturing the bulk
of the distribution.
9
higher predictive power[24]. However, a longer fingerprint of length 1024 did not provide a large
improvement in terms of the activity covariance (Equation 9) in these data as shown by Figure
2C. Hence, we decided to use the 128 fingerprint which is less likely to overfit.
2.4 Data and Code Availability
The code required to download directly from ChEMBL all these data sets, as well as the as-
say IDs for all of them, is available on the accompanying GitHub repository for this article:
https://github.com/owatson/PenalizedPrediction.
3 Results
3.1 Semi-supervised framework for predicting highly active compounds
Using Bayes rule, conditioning on (i) whether a novel compound is active and (ii) on the setwise
distance between the compound and the training data, we formulate a predictive framework which
adjusts for the selection bias inherent in many structure activity datasets. The rationale for this
approach is that the labelled data - the available structure-activity data - are highly biased due
to reporting selection bias (only reporting compounds with an activity level greater than some
cutoff). In addition we take into account the empirical degradation of predictive performance as a
function of the distance between the testing compound and the training compounds. The goal is to
obtain a model that can make unbiased predictions of activity for a previously unseen compound,
explicitly adjusting for the degradation in predictive performance as a function of the distance
to the training data. This framework requires three elements. Firstly, a metric over the space
of small molecules whereby the distance between compounds explains a significant proportion of
the covariance between their activities (in our case more than 50%). Secondly, we require a set
of unlabelled (no corresponding activity measurements) compounds which are assumed to have
been sampled under approximately the same data generating process as the labelled compounds,
but without activity dependent reporting bias. Thirdly, we require an estimate of the background
frequency of the discovery of active compounds under the data generating process.
The framework does the following:
1. We determine the probability of being active as a function of the distance to the training
data, as given by Equation (4).
2. We determine how the predictive accuracy of the model degrades as a function of the distance
to the training data (Equation (6)).
3. Determine how the covariance of the activity of two active elements varies as a function of
the distance between them.
4. Given some model for the full distribution of activity values of the active compounds (as
a function of variance and expected activity level) - put the above three steps together to
compute, for any unknown compound, the full posterior distribution of its activity.
In Figure 2, we illustrate the above four steps. Panel A shows the plot of the estimated
probability that an unknown compound is active as a function of its distance δ to the training set
comprised of only active compounds. Panel B plots the estimate of the degradation of predictive
accuracy (model strength) as a function of δ, for the two types of models we examine (ridge and
random forest). Panel C shows how the covariance of two active compounds increases the further
apart they are. This distance-dependent covariance is used to estimate the variance (and thus the
standard deviation) of the activity of an unknown compound as a function of its distance to the
known compounds in the training data. In addition, panel C shows how the observed covariances
for the 128-bit fingerprint and the 1024-bit fingerprint compare: only marginal improvements are
made with a more complex fingerprint representation.
Panel D merges these components and illustrates how the fully adjusted model (score S3)
works. We confine our attention to the random forest model. Rather than trying to plot the full
predictive distribution as a function of δ for some compound (which would thus be a surface),
we plot probability contour lines. Given some unknown compound x, at distance δ to the active
training set, suppose that S0(x)(= Mˆ(x
∗|Xqtrain )) is the simple estimate from the random forest
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model (without any adjustment of any kind) for the activity of x. We call this value the ‘start
point’. Given some target level of activity T , we wish to plot the log probability that y(x) >= T
as a function of δ. We compute the probability that x ∈ A as a function of δ. Then, assuming
x ∈ A, we compute the distribution of y(x). For this, we require three items:
1. µ(δ) := E [y(x))|x ∈ A]. This is the score S1(x), which is S0(x) adjusted towards the mean
activity level as a function of δ.
2. σ(δ) := E [y(x)− y(a)]2 where a ∈ A is the closest compound to x. We obtain this from the
potency covariance plot (bottom left in Figure 2) as a function of δ.
3. The distribution of y(x)|x ∈ A as a function of µ(δ) and σ(δ). Here we use the distribution
fit shown in the lower panel of Figure 1, but with our new estimates of µ(δ) and σ(δ). Once
we have the distribution, we can read off the probability mass that lies above T .
3.2 Application to Plasmodium falciparum screening data
We analysed structure activity data on 13,533 compounds that were selected on the basis inhibiting
P. falciparum 3D7 growth by more than 80% at 2 microMol [4]. To assess the benefit of using the
semi-supervised framework, we compared the predictive performance between the derived semi-
supervised predictive model (score S3) and the standard fully supervised predictive model that does
not use the unlabelled data (score S0). Scores S1 and S2 are intermediate versions of the semi-
supervised framework. The comparison between predictive frameorks (i.e. scores) was done using
quantile-activity splitting [20]. This uses all compounds with activity below a certain threhsold as
training data, and all compounds with activity above a certain threhsold as testing data.
We fit random forests and ridge regression models to two separate training sets: all compounds
with activity less than 7 pIC50 and all compounds with activity less than 7.5 pIC50. Two separate
testing sets were used: all compounds with activity greater than 7.5 pIC50 (n=237), and all
compounds with activity greater than 8 pIC50 (n=170). The predictive performance of each fitted
model was then assessed under four different predictive frameworks (scores S0 to S3, see section
2.2.4).
A comparison of these four predictive frameworks is shown in Figure 3 for random forests and
in Figure 4 for ridge regression. For simplicity we show the results when training on compounds
with activity less than 7 and testing on compounds greater than 8 (upper panels); and when
training on compounds with activity less than 7.5 and testing on compounds with activity greater
than 7.5 (lower panels). Each panel shows the percentage of true compounds (compounds in the
TCAMS data not used in the model training stage and known to have activity above the desired
threshold) discovered as a function of the number of compounds chosen from the testing set (500
000 compounds in total). For a choice of 1000 compounds - a reasonable size for a drug discovery
project - the naive model (score S0) performs consistently worse across all experiments that the
full predictive framework (score S3). For example, in the most difficult testing scenario, where the
training data are all compounds with activity less than 7, and the testing compounds are those with
activity greater than 8, then S3 selects more active compounds than S0 in the first N compounds
for N up to around 10, 000 when the underlying model is random forests, and even more so when
the underlying model is ridge regression.
4 Discussion
Our goal in this paper was to build QSAR models that fulfil two key goals. Firstly, for any given
testing compound, the predicted activity is “sensible”. By sensible we mean that the prediction
takes into account the distance dependent degradation. This implies that for testing compounds
whose structures are entirely different to all training compounds, the model’s prediction will be
based on the background discovery rate of active compounds and the mean activity of the active
compounds. Secondly, the model predictions should be “useful”. By useful we mean that the
adjusted model should outperform a ‘naive’ model at distinguishing ‘good’ compounds. We use a
quantile-activity split approach to set up model testing experiments. These two goals appear to
be well aligned but they are not easy to jointly satisfy. For instance, the non-adjusted (‘naive’)
random forest model (score S0), only using the labelled data, performs almost as well as the fully
adjusted model (score S3) in identifying high-activity compounds in the training data (Figure 3).
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Figure 3: Comparison of predictive scores whereby random forests is the underlying predictive
model. Here the y-axis is % of active compounds found within the first x compounds ordered by
the selection methodology.
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However, the non-adjusted model does not make sensible predictions overall, since it predicts a
non-negligible asexual activity against P. falciparum 3D7 for any input compound. Method S2
does make sensible predictions by correctly predicting the average activity values for all compounds
(due to the distance-dependent adjustment), but underperforms S0 substantially in three of our
four testing experiments setups. Indeed, a simple example of a sensible, but completely useless
model is one that predicts the background adjusted mean activity level for any compound.
We show that these two goals can be achieved by explicitly modelling the full distribution of
our prediction, rather than just the mean value, and taking this distribution into account in the
optimization process. The method that does this (S3 in Figures 3 and 4) is the top performing
method for choosing compounds overall. It is the top performing method in four of the eight tests
performed, and no other method consistently dominates it (the closest is method S1, which, like
S0, does not make sensible predictions overall).
The utility of having a general predictive model framework that performs both these goals
is that it opens up new questions for quantitative analysis, and in particular optimization. For
optimization algorithms to converge, they need not only to produce accurate answers on the domain
of interest (what we call a ‘useful’ model), but they also need to provide at least approximately
correct answers outside that domain (what we call a ‘sensible’ model). In our testing experiments,
all the methods tested (S0 to S3) provide rankings of all compounds. However the fully adjusted
model (score S3) has an additional advantage. The rank it provides for a given compound is derived
from the probability that the compound will an activity above a threshold of interest. Thus given
three compounds x0, x1, x2, with S3(x0) > S3(x1) > S3(x2), we can ask the question ‘would we
have a higher chance of finding at least one compound with an activity above the threshold of
interest if we tested x1 and x2, rather than just x0? This question cannot be answered by the
other model adjustments, and this example can of course be extensively generalized. Most of the
practical questions that face researchers in this area are in terms of tradeoffs, e.g. “how many
compounds should we make in one batch?”; “how similar should they be?”; “is it work making one
expensive compound that is predicted to be highly active, or testing ten cheap ones that are not
predicted to be quite as good?”[25, 26]. We hope that this approach will make predictive models
substantially more useful to practitioners.
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